Taysha Gene Therapies (TSHA) versus Its Rivals Financial Survey

Taysha Gene Therapies (NASDAQ:TSHA) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Taysha Gene Therapies to related businesses based on the strength of its profitability, institutional ownership, dividends, risk, valuation, analyst recommendations and earnings.

Institutional & Insider Ownership

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Taysha Gene Therapies and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Taysha Gene Therapies Competitors	-9,054.47%	-198.89%	-30.64%

Analyst Ratings

This is a summary of recent ratings for Taysha Gene Therapies and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1	0	12	2	3.00
Taysha Gene Therapies Competitors	9782	15046	45274	1571	2.54

Taysha Gene Therapies presently has a consensus price target of $12.77, indicating a potential upside of 219.23%. As a group, “Biotechnology” companies have a potential upside of 99.61%. Given Taysha Gene Therapies’ stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than its peers.

Earnings & Valuation

This table compares Taysha Gene Therapies and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Taysha Gene Therapies	$9.77 million	-$109.00 million	-9.52
Taysha Gene Therapies Competitors	$730.05 million	$13.53 million	-10.01

Taysha Gene Therapies’ peers have higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Taysha Gene Therapies has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies’ peers have a beta of 1.11, indicating that their average share price is 11% more volatile than the S&P 500.

Summary

Taysha Gene Therapies beats its peers on 9 of the 13 factors compared.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.